DXR

DAXOR CORP (DXR) - 10-K Summary for Fiscal Year Ended December 31, 2002

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2002. Daxor Corporation is a medical device manufacturer and biotech service provider. Its primary focus is the BVA-100 Blood Volume Analyzer, an FDA-cleared instrument that rapidly measures human blood volume to aid in diagnosing conditions such as syncope, hypertension, and septic shock. The company also operates Scientific Medical Systems, a wholly-owned subsidiary providing long-term autologous blood banking and semen banking services through its Idant division.

Key Financial Metrics

Note: The company's financial results are heavily influenced by a diversified portfolio of utility stocks, which generated approximately $1.86 million in dividend income in 2002.

Material Changes vs. Prior Period

• Operating Revenue Growth: Operating revenues increased 30% to $767,608 from $591,692 in 2001, driven by increased marketing efforts and sales of the BVA-100 analyzer.
• Net Loss: The company reported a net loss of $193,851 in 2002, a reversal from the $299,355 net profit in 2001. This was primarily due to a significant increase in total costs and expenses ($2.87 million vs. $2.35 million), attributed to hiring new sales personnel and increased marketing expenditures.
• Liquidity Decline: Cash and cash equivalents dropped significantly from $431,949 to $13,035. This decrease was driven by a net cash outflow from operating activities ($212,772) and financing activities ($409,535), including a $300,000 bank loan repayment and $109,535 in treasury stock purchases.
• Debt Fluctuation: While the bank loan decreased from $1,000,000 to $700,000, short-term margin debt due to brokers increased to $734,046, resulting in a net increase in total short-term debt.

Outlook, Management Commentary, and Risks

Management Strategy: Management intends to focus major marketing efforts on the BVA-100 Blood Volume Analyzer, viewing it as the primary future revenue source. The company hired a National Sales Manager and regional managers in late 2002 to expand sales. They plan to utilize a leasing model through a partnership with De Lage Landen to reduce capital outlay for equipment.

Market Potential: The company estimates a potential market of 15-20 million tests per year. They believe successful penetration of even a small fraction of this market would significantly alter the company's structure.

Risks and Contingencies:

• Liquidity Risk: The company plans its budget assuming that raising additional capital may be difficult in the next 2 to 4 years. Cash reserves are low ($13,035).
• Investment Dependency: Operating losses are currently offset by income from a securities portfolio. A decline in this portfolio's value or dividend yield could severely impact the company's ability to fund operations.
• Market Acceptance: The primary hindrance to growth is demonstrating the cost-effectiveness and accuracy of the BVA-100 to the medical community.

Investor Verification Checklist

• Operating Cash Flow: Verify the sustainability of operations given the negative operating cash flow of $(212,772) and minimal cash on hand.
• Investment Portfolio Performance: Assess the stability of the $40.5 million securities portfolio, which provides the majority of total revenue, and the impact of unrealized gains on equity.
• Sales Execution: Confirm the progress of the new sales team hired in late 2002 and the conversion rate of marketing efforts into BVA-100 unit sales or leases.
• Debt Covenants: Review the terms of the $1.43 million in short-term debt, specifically the margin debt secured by marketable securities, to understand potential liquidation risks if security values decline.
• Reimbursement Status: Verify current Medicare and insurance reimbursement rates for blood volume testing, as this is critical for hospital adoption.